Trial Profile
An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 05 Jan 2024 Planned End Date changed from 1 Dec 2023 to 30 Mar 2024.
- 15 Dec 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
- 17 Dec 2021 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.